Literature DB >> 30053139

Hepcidin, iron indices and bone mineral metabolism in non-dialysis chronic kidney disease.

Hyang Ki Min1, Su Ah Sung1, Yun Kyu Oh2, Yeong Hoon Kim3, Wookyung Chung4, Sue K Park5,6,7, Curie Ahn8, Sung Woo Lee1.   

Abstract

BACKGROUND: Few studies have examined the association between hepcidin, iron indices and bone mineral metabolism in non-dialysis chronic kidney disease (CKD) patients.
METHODS: We reviewed the data of 2238 patients from a large-scale multicenter prospective Korean study (2011-16) and excluded 214 patients with missing data on markers and related medications of iron and bone mineral metabolism, hemoglobin, blood pressure and causes of CKD. Multivariate linear regression analysis was used to identify the association between iron and bone mineral metabolism.
RESULTS: The proportion of CKD Stages 1-5 were 16.2, 18.7, 37.1, 21.6 and 6.4%, respectively. Per each 10% increase in transferrin saturation (TSAT), there was a 0.013 mmol/L decrease in phosphorus [95% confidence interval (CI) -0.021 to -0.004; P = 0.003] and a 0.022 nmol/L increase in logarithmic 25-hydroxyvitamin D (Ln-25OHD) levels (95% CI 0.005-0.040; P = 0.019). A 1 pmol/L increase in Ln-ferritin was associated with a 0.080 ng/L decrease in Ln-intact parathyroid hormone (Ln-iPTH; 95% CI -0.122 to -0.039; P < 0.001). Meanwhile, beta (95% CI) per 1 unit increase in phosphorus, Ln-25OHD and Ln-iPTH for the square root of the serum hepcidin were 0.594 (0.257-0.932; P = 0.001), -0.270 (-0.431 to -0.108; P = 0.001) and 0.115 (0.004-0.226; P = 0.042), respectively. In subgroup analysis, the relationship between phosphorus, 25OHD and hepcidin was strongest in the positive-inflammation group.
CONCLUSIONS: Markers of bone mineral metabolism and iron status, including hepcidin, were closely correlated to each other. Potential mechanisms of the relationship warrant further studies.
© The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  bone mineral metabolism; chronic kidney disease; hepcidin; iron

Year:  2020        PMID: 30053139     DOI: 10.1093/ndt/gfy235

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  3 in total

1.  Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.

Authors:  Connor Francis; Guillaume Courbon; Claire Gerber; Samantha Neuburg; Xueyan Wang; Corey Dussold; Maralee Capella; Lixin Qi; Tamara Isakova; Rupal Mehta; Aline Martin; Myles Wolf; Valentin David
Journal:  Kidney Int       Date:  2019-08-30       Impact factor: 10.612

Review 2.  The KNOW-CKD Study: What we have learned about chronic kidney diseases.

Authors:  Kook-Hwan Oh; Minjung Kang; Eunjeong Kang; Hyunjin Ryu; Seung Hyeok Han; Tae-Hyun Yoo; Soo Wan Kim; Dong-Wan Chae; Kyu-Beck Lee; Sue K Park; Yeong Hoon Kim; Curie Ahn
Journal:  Kidney Res Clin Pract       Date:  2020-06-30

3.  Relationship between Cardiac Geometry and Serum Hepcidin in Chronic Kidney Disease: Analysis from the KNOW-CKD Study.

Authors:  Hyang Ki Min; Yun Kyu Oh; Kyu Hun Choi; Kyu Beck Lee; Sue K Park; Curie Ahn; Sung Woo Lee
Journal:  J Korean Med Sci       Date:  2020-01-06       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.